Coldstream Capital Management Inc. Acquires 1,710 Shares of Insulet Co. (NASDAQ:PODD)

Coldstream Capital Management Inc. increased its holdings in shares of Insulet Co. (NASDAQ:PODD) by 144.5% during the 3rd quarter, HoldingsChannel reports. The firm owned 2,893 shares of the medical instruments supplier’s stock after purchasing an additional 1,710 shares during the period. Coldstream Capital Management Inc.’s holdings in Insulet were worth $714,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PODD. QRG Capital Management Inc. acquired a new position in Insulet in the 3rd quarter worth $297,000. Fisher Asset Management LLC lifted its holdings in shares of Insulet by 0.9% in the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after purchasing an additional 3,113 shares in the last quarter. Nomura Asset Management Co. Ltd. boosted its position in shares of Insulet by 5.7% during the third quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock worth $35,708,000 after buying an additional 8,301 shares during the period. Orion Portfolio Solutions LLC grew its holdings in shares of Insulet by 86.2% during the third quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock worth $1,822,000 after buying an additional 3,623 shares in the last quarter. Finally, Point72 DIFC Ltd acquired a new stake in Insulet in the 2nd quarter valued at approximately $554,000.

Insulet Stock Performance

PODD opened at $269.34 on Friday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $279.77. The business has a 50 day moving average of $251.37 and a 200-day moving average of $220.02. The stock has a market cap of $18.89 billion, a price-to-earnings ratio of 46.12, a PEG ratio of 4.18 and a beta of 1.21.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on PODD shares. Sanford C. Bernstein began coverage on Insulet in a research report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price target for the company. JPMorgan Chase & Co. boosted their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday. Citigroup raised their target price on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday. Morgan Stanley boosted their price target on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. Finally, Raymond James raised their price objective on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, Insulet has a consensus rating of “Moderate Buy” and a consensus price target of $267.44.

Insider Activity at Insulet

In other Insulet news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.47% of the stock is owned by company insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.